Ataxia Telangiectsia
Conditions
Interventions
Medication
Betamethason(Rinderon) Medication regimen
0.02mg/kg/day (per oral) once a day for 20 days. Repeat this regimen with 20 days interval. Duration of trial
4 years. Observation
5 years.
Sponsors
Research group for establishment of diagnostic procedure, Clinical status and etiology for Ataxia Telangiectasia
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Ataxia Telangiectasia 2)<20 years old 3)Performance Status0-2 4)NCI-CTC (National Cancer Institute; Common Toxicity Criteria) Grade I or less 5)one who obtained consent from guardian. One who obtained consent, if participant is more than 16 years old and communication is available.
Exclusion criteria
Exclusion criteria: 1) one who carries infection 2) one who carries serious complication 3) one who carries malignancy 4) one who judged inadequate by investigator 5) one who participated to any clinical trial within past 3 month
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of ataxia evaluated by neurological scale for ataxia | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effects due to steroid, such as glucose intolerance, adrenal function, immunological status, frequency of cancer development and oxidation marker | — |
Countries
Japan
Contacts
Public ContactMasatoshi Takagi
Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences Developmental Biology Section
Outcome results
None listed